TUSTIN, Calif., April 09, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the International Pharmaceutical Expo (INTERPHEX) 2018. The company’s activities will include participation in a conference panel focused on biologics outsourcing, as well as delivering a presentation on single-use manufacturing of biopharmaceuticals. INTERPHEX 2018 is being held April 17-19, 2018 at the Javits Center in New York, NY.
Details of Avid’s activities at INTERPHEX 2018 are as follows:
- Roger Lias, Ph.D., Avid’s president and chief executive officer, will participate on a conference panel titled, “Biologics Outsourcing.” The panel will take place from 2:15 – 3:00 p.m. Eastern on Wednesday, April 18th at booth #1053 within the CMO Theatre. The CMO Theatre is part of the conference’s dedicated CMO/CDMO Pavilion, which is being hosted by the Pharma and Biopharma Outsourcing Association (PBOA).
- Sun Ra Bullins, director of manufacturing at Avid, will make a presentation titled, “The Perks and Pitfalls of a Single-Use Biopharmaceutical Facility.” The presentation will take place from 11:30 a.m. – 12:15 p.m. Eastern on Tuesday, April 17th at booth #1053 within the CMO Theatre.
Sponsored by the Parenteral Drug Association (PDA), INTERPHEX brings over 11,000 global industry professionals and more than 630 industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of no cost technical conference, exhibits, demonstrations, roundtables, partnering opportunities and networking to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market. For additional details on INTERPHEX 2018, please visit: http://www.interphex.com/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]


Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Amazon Explores AI Content Marketplace With Media Publishers
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 



